Deregulating the rapidly evolving digital health industry

FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update

FierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown

BioPharma DiveInnovation alone is no longer enough in biopharma

BioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalability

Roche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.com

FierceBiotechCould engaging the immune system improve AML outcomes?

FierceBiotechWhy AI is changing clinical development

FierceBiotechManaging complexity across biopharma modalities

NINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects

IlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo Finance

FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect